Synapse - Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms Journal Article

Authors:	Durham, B. H.; Lopez Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S. X.; Pastore, A.; Yoshimi, A.; Mandelker, D.; Ceyhan-Birsoy, O.; Ulaner, G. A.; Walsh, M.; Yabe, M.; Petrova-Drus, K.; Arcila, M. E.; Ladanyi, M.; Solit, D. B.; Berger, M. F.; Hyman, D. M.; Lacouture, M. E.; Erickson, C.; Saganty, R.; Ki, M.; Dunkel, I. J.; Santa-María López, V.; Mora, J.; Haroche, J.; Emile, J. F.; Decaux, O.; Geissmann, F.; Savvides, S. N.; Drilon, A.; Diamond, E. L.; Abdel-Wahab, O.
Article Title:	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Abstract:	Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in patients with histiocytosis. © 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.
Journal Title:	Nature Medicine
Volume:	25
Issue:	12
ISSN:	1078-8956
Publisher:	Nature Publishing Group
Date Published:	2019-12-01
Start Page:	1839
End Page:	1842
Language:	English
DOI:	10.1038/s41591-019-0653-6
PUBMED:	31768065
PROVIDER:	scopus
PMCID:	PMC6898787
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075425733&doi=10.1038%2fs41591-019-0653-6&partnerID=40&md5=6bc3c6828100ec6f3622df9178501450
Notes:	Article -- Export Date: 2 January 2020 -- Source: Scopus